Drug Patents Expiring in 2027

1. Drug name - ABILIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders Mar, 2027

(4 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

2. Drug name - ABILIFY MYCITE KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders Mar, 2027

(4 years from now)

US9444503 OTSUKA Active signal processing personal health signal receivers Nov, 2027

(5 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Adjunctive treatment of major depressive disorder (mdd); Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription
30MG TABLET;ORAL Prescription

3. Drug name - ABRAXANE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8034375

(Pediatric)

ABRAXIS BIOSCIENCE Combinations and modes of administration of therapeutic agents and combination therapy Feb, 2027

(4 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

4. Drug name - ACTOPLUS MET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101660 TAKEDA PHARMS USA Solid preparation Jan, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
500MG;EQ 15MG BASE TABLET;ORAL Prescription
850MG;EQ 15MG BASE TABLET;ORAL Prescription

5. Drug name - ACULAR LS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8008338

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain Nov, 2027

(5 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.4% SOLUTION/DROPS;OPHTHALMIC Prescription

6. Drug name - ADRENACLICK

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7905352 IMPAX Kits containing medicine injection devices and containers Apr, 2027

(4 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.15MG/DELIVERY INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS Discontinued
EQ 0.3MG/DELIVERY INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

7. Drug name - ADVIL ALLERGY SINUS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287 GLAXOSMITHKLINE Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines Feb, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
2MG;200MG;30MG TABLET;ORAL Over the counter

8. Drug name - ALSUMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7811254 MERIDIAN MEDCL Autoinjector with needle depth adapter Aug, 2027

(4 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) INJECTABLE;SUBCUTANEOUS Discontinued

9. Drug name - ALTABAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7875630 ALMIRALL Process salts compositions and use
Feb, 2027

(4 years from now)

Drugs and Companies using RETAPAMULIN ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% OINTMENT;TOPICAL Prescription

10. Drug name - AMITIZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8338639 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation Jan, 2027

(4 years from now)

US8779187 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation Jan, 2027

(4 years from now)

US8026393 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation Oct, 2027

(5 years from now)

Drugs and Companies using LUBIPROSTONE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
8MCG CAPSULE;ORAL Prescription
24MCG CAPSULE;ORAL Prescription

11. Drug name - AMYVID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8506929 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(4 years from now)

US7687052 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(4 years from now)

CN101522624B AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

CN101522624A AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

IN288160B AVID RADIOPHARMS INC Styrylpyridine Compounds
Mar, 2027

(4 years from now)

IN200807219P1 AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

EP2363392A1 AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

EP2363392B1 AVID RADIOPHARMS INC Styrylpyridine Derivatives And Their Use For Binding And Imaging Amyloid Plaques
Mar, 2027

(4 years from now)

Drugs and Companies using FLORBETAPIR F-18 ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10ML (13.5-51mCi/ML) SOLUTION;INTRAVENOUS Discontinued
10-30ML (13.5-51mCi/ML) SOLUTION;INTRAVENOUS Prescription
10-50ML (13.5-51mCi/ML) SOLUTION;INTRAVENOUS Prescription

12. Drug name - ANORO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304 GLAXOSMITHKLINE Medicament dispenser Jun, 2027

(4 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

13. Drug name - ANTIZOL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553863 PAR PHARM INC Ultrapure 4-methylpyrazole
Jun, 2027

(4 years from now)

Drugs and Companies using FOMEPIZOLE ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage
Strength Dosage Availability
1.5GM/1.5ML (1GM/ML) INJECTABLE;INJECTION Discontinued

14. Drug name - ARGATROBAN IN SODIUM CHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7687516 EAGLE PHARMS Alcohol free formulation of argatroban Sep, 2027

(4 years from now)

US7589106 EAGLE PHARMS Alcohol free formulation of argatroban Sep, 2027

(4 years from now)

Drugs and Companies using ARGATROBAN ingredient

Treatment: Method of treating an argatroban treatable condition; Method of treating thrombosis

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
50MG/50ML (1MG/ML) INJECTABLE;INTRAVENOUS Discontinued

15. Drug name - ARNUITY ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXOSMITHKLINE Medicament dispenser Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.05MG/INH POWDER;INHALATION Prescription
0.1MG/INH POWDER;INHALATION Prescription
0.2MG/INH POWDER;INHALATION Prescription

16. Drug name - AUBAGIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410

(Pediatric)

SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis Mar, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
7MG TABLET;ORAL Prescription
14MG TABLET;ORAL Prescription

17. Drug name - AUVI-Q

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system Feb, 2027

(4 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery Feb, 2027

(4 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery May, 2027

(4 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.15MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription
EQ 0.3MG/DELIVERY SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Prescription

18. Drug name - AVEED

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels Mar, 2027

(4 years from now)

US8338395 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels May, 2027

(4 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired); hypogonadotropic hypogonadism (congenital or acquired).

Dosage: INJECTABLE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
750MG/3ML (250MG/ML) INJECTABLE;INTRAMUSCULAR Prescription

19. Drug name - AXIRON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9289586 ELI LILLY AND CO Spreading implement Feb, 2027

(4 years from now)

US8419307 ELI LILLY AND CO Spreading implement Feb, 2027

(4 years from now)

US8807861 ELI LILLY AND CO Spreading implement Feb, 2027

(4 years from now)

US8435944 ELI LILLY AND CO Method and composition for transdermal drug delivery Sep, 2027

(4 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of increasing the testosterone blood level of a person in need thereof; A method of transdermal administration of a physiologically active agent to a subject.

Dosage: SOLUTION, METERED;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
30MG/1.5ML ACTUATION SOLUTION, METERED;TRANSDERMAL Discontinued

20. Drug name - AZILECT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7815942 TEVA Rasagiline formulations of improved content uniformity
Aug, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG BASE TABLET;ORAL Prescription
EQ 1MG BASE TABLET;ORAL Prescription

21. Drug name - BALCOLTRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7838042 AVION PHARMS Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions
Jun, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
0.02MG;0.1MG TABLET;ORAL Prescription

22. Drug name - BAXDELA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7728143 MELINTA Salt and crystalline forms thereof of a drug
Nov, 2027

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 300MG BASE/VIAL POWDER;INTRAVENOUS Prescription

23. Drug name - BELBUCA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655843 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US8147866 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Treatement of pain by transmucosal delivery of buprenorphine

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 0.075MG BASE FILM;BUCCAL Prescription
EQ 0.15MG BASE FILM;BUCCAL Prescription
EQ 0.3MG BASE FILM;BUCCAL Prescription
EQ 0.45MG BASE FILM;BUCCAL Prescription
EQ 0.6MG BASE FILM;BUCCAL Prescription
EQ 0.75MG BASE FILM;BUCCAL Prescription
EQ 0.9MG BASE FILM;BUCCAL Prescription

24. Drug name - BELEODAQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH Pharmaceutical formulations of HDAC inhibitors Oct, 2027

(5 years from now)

Drugs and Companies using BELINOSTAT ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/VIAL POWDER;INTRAVENOUS Prescription

25. Drug name - BREO ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304 GLAXO GRP LTD Medicament dispenser Jun, 2027

(4 years from now)

US9333310 GLAXO GRP LTD Medicament dispenser Oct, 2027

(4 years from now)

US8113199 GLAXO GRP LTD Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bronchitis and/or emphysema, also to reduce exacerbations of copd in patients with a history of exacerbations

Dosage: POWDER;INHALATION

More Information on Dosage
Strength Dosage Availability
0.1MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription
0.2MG/INH;EQ 0.025MG BASE/INH POWDER;INHALATION Prescription

26. Drug name - BUNAVAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655843 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

US8147866 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Treatment: Treatment of opioid dependence; Maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 2.1MG BASE;EQ 0.3MG BASE FILM;BUCCAL Discontinued
EQ 4.2MG BASE;EQ 0.7MG BASE FILM;BUCCAL Discontinued
EQ 6.3MG BASE;EQ 1MG BASE FILM;BUCCAL Discontinued

27. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes Feb, 2027

(4 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8758292 ASTRAZENECA AB Administering apparatus with functional drive element Nov, 2027

(5 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Dec, 2027

(5 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

28. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes Feb, 2027

(4 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Dec, 2027

(5 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

29. Drug name - BYFAVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms Jul, 2027

(4 years from now)

US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms Jul, 2027

(4 years from now)

US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms Jul, 2027

(4 years from now)

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE/VIAL POWDER;INTRAVENOUS Prescription

30. Drug name - BYVALSON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838552 ALLERGAN Compositions comprising nebivolol Oct, 2027

(5 years from now)

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Treatment: Method of treating hypertension

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE;80MG TABLET;ORAL Discontinued

31. Drug name - CAMCEVI KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572857 ACCORD Pharmaceutical compositions with enhanced stability Jan, 2027

(4 years from now)

US10646572 ACCORD Pharmaceutical compositions with enhanced stability Jan, 2027

(4 years from now)

US9744207 ACCORD Pharmaceutical compositions with enhanced stability Jan, 2027

(4 years from now)

Drugs and Companies using LEUPROLIDE MESYLATE ingredient

Treatment: NA

Dosage: EMULSION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 42MG BASE EMULSION;SUBCUTANEOUS Prescription

32. Drug name - CARDENE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions Apr, 2027

(4 years from now)

US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions Apr, 2027

(4 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions Apr, 2027

(4 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions Dec, 2027

(5 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions Dec, 2027

(5 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
25MG/10ML (2.5MG/ML) INJECTABLE;INJECTION Discontinued
40MG/200ML (0.2MG/ML) INJECTABLE;INTRAVENOUS Discontinued
20MG/200ML (0.1MG/ML) INJECTABLE;INTRAVENOUS Prescription

33. Drug name - CHLORAPREP ONE-STEP

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7422388 BECTON DICKINSON CO Applicator for coloring antiseptic Apr, 2027

(4 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SPONGE;TOPICAL

More Information on Dosage
Strength Dosage Availability
2%;70% (3ML) SPONGE;TOPICAL Over the counter
2%;70% (10.5ML) SPONGE;TOPICAL Over the counter
2%;70% (26ML) SPONGE;TOPICAL Over the counter
2%;70% (1ML) SPONGE;TOPICAL Over the counter
2%;70% (1.5ML) SPONGE;TOPICAL Over the counter

34. Drug name - CHLORHEXIDINE GLUCONATE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7935093 SAGE PRODS Disinfectant delivery system and method of providing alcohol-free disinfection Oct, 2027

(4 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Treatment: For the preparation of skin prior to surgery; helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% CLOTH;TOPICAL Over the counter

35. Drug name - COLAZAL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7452872

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives Feb, 2027

(4 years from now)

US7625884

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives Feb, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
750MG CAPSULE;ORAL Prescription

36. Drug name - COMBIVENT RESPIMAT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component Mar, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE/INH;0.02MG/INH SPRAY, METERED;INHALATION Prescription

37. Drug name - CONTRAVE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107837 NALPROPION Sustained release formulation of naltrexone Jun, 2027

(4 years from now)

US8722085 NALPROPION Methods for administering weight loss medications Nov, 2027

(5 years from now)

US8318788 NALPROPION Layered pharmaceutical formulations Nov, 2027

(5 years from now)

US10307376 NALPROPION Methods for administering weight loss medications Nov, 2027

(5 years from now)

US9125868 NALPROPION Methods for administering weight loss medications Nov, 2027

(5 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion based on an escalating dose schedule; Use of naltrexone and bupropion in a layered formulation for chronic weight management for affecting weight loss

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
90MG;8MG TABLET, EXTENDED RELEASE;ORAL Prescription

38. Drug name - CORLANOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7867996

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it Jun, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 7.5MG BASE TABLET;ORAL Prescription

39. Drug name - CRESEMBA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof Sep, 2027

(4 years from now)

US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof Sep, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
186MG CAPSULE;ORAL Prescription

40. Drug name - DAKLINZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9421192 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

US8642025 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

CN101558059B BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitor
Aug, 2027

(4 years from now)

CN104447707A BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

CN101558059A BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

CN104447707B BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

EP2784075A1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

EP2784075B1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

EP3042901A1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

EP3042901B1 BRISTOL-MYERS SQUIBB Hepatitis C Virus Inhibitors
Aug, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900566 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors Aug, 2027

(4 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 30MG BASE TABLET;ORAL Discontinued
EQ 60MG BASE TABLET;ORAL Discontinued
EQ 90MG BASE TABLET;ORAL Discontinued

41. Drug name - DEXILANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7790755

(Pediatric)

TAKEDA PHARMS USA Controlled release preparation Feb, 2027

(4 years from now)

US8105626

(Pediatric)

TAKEDA PHARMS USA Granules containing acid-unstable chemical in large amount Mar, 2027

(4 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
30MG CAPSULE, DELAYED RELEASE;ORAL Prescription
60MG CAPSULE, DELAYED RELEASE;ORAL Prescription

42. Drug name - DIFICID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
Jul, 2027

(4 years from now)

US7378508 CUBIST PHARMS LLC Polymorphic crystalline forms of tiacumicin B
Jul, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7906489 CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof Mar, 2027

(4 years from now)

US8859510 CUBIST PHARMS LLC Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jul, 2027

(4 years from now)

US7863249 CUBIST PHARMS LLC Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof Jul, 2027

(4 years from now)

US7906489

(Pediatric)

CUBIST PHARMS LLC 18-membered macrocycles and analogs thereof Sep, 2027

(4 years from now)

Drugs and Companies using FIDAXOMICIN ingredient

Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Prescription

43. Drug name - DOVATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;300MG TABLET;ORAL Prescription

44. Drug name - DSUVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9744129 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain Jan, 2027

(4 years from now)

US8252329 ACELRX PHARMS Bioadhesive drug formulations for oral transmucosal delivery Jan, 2027

(4 years from now)

US8778393 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain Jan, 2027

(4 years from now)

US8252328 ACELRX PHARMS Bioadhesive drug formulations for oral transmucosal delivery Jan, 2027

(4 years from now)

US10245228 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain Jan, 2027

(4 years from now)

US10507180 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain Jan, 2027

(4 years from now)

US8535714 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain Jan, 2027

(4 years from now)

US8865211 ACELRX PHARMS Bioadhesive drug formulations for oral transmucosal delivery Jan, 2027

(4 years from now)

US8778394 ACELRX PHARMS Small-volume oral transmucosal dosage forms Jan, 2027

(4 years from now)

US10342762 ACELRX PHARMS Small-volume oral transmucosal dosage forms Jan, 2027

(4 years from now)

US8226978 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain Jan, 2027

(4 years from now)

US9320710 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain Jan, 2027

(4 years from now)

US8231900 ACELRX PHARMS Small-volume oral transmucosal dosage Jan, 2027

(4 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 0.03MG BASE TABLET;SUBLINGUAL Prescription

45. Drug name - DUAKLIR PRESSAIR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8051851 ASTRAZENECA Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler Apr, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
0.4MG/INH;0.012MG/INH POWDER, METERED;INHALATION Prescription

46. Drug name - DUAVEE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7683051 WYETH PHARMS Crystalline polymorph of bazedoxifene acetate
Mar, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE;0.45MG TABLET;ORAL Prescription

47. Drug name - DUETACT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700128 TAKEDA PHARMS USA Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester Jan, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
2MG;30MG TABLET;ORAL Prescription
4MG;30MG TABLET;ORAL Prescription

48. Drug name - DURYSTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8206737 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods Apr, 2027

(4 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
10MCG IMPLANT;OPHTHALMIC Prescription

49. Drug name - DYANAVEL XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10086087 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes Mar, 2027

(4 years from now)

US8597684 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes Mar, 2027

(4 years from now)

US8883217 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes Mar, 2027

(4 years from now)

US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes Mar, 2027

(4 years from now)

US9675703 TRIS PHARMA INC Modified release formulations containing drug - ion exchange resin complexes Mar, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
2MG/ML;EQ 0.5MG BASE/ML SUSPENSION, EXTENDED RELEASE;ORAL Prescription

50. Drug name - DYANAVEL XR 10

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8337890 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes Mar, 2027

(4 years from now)

US9675704 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes Mar, 2027

(4 years from now)

US8747902 TRIS PHARMA INC Modified release formulations containing drug-ion exchange resin complexes Mar, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
8MG;EQ 2MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
12MG;EQ 3MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
16MG;EQ 4MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
4MG;EQ 1MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

51. Drug name - DYLOJECT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946292 JAVELIN PHARMS INC Formulations of low dose diclofenac and beta-cyclodextrin Mar, 2027

(4 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Management of pain

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
37.5MG/ML (37.5MG/ML) SOLUTION;INTRAVENOUS Discontinued

52. Drug name - EDLUAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597281 MYLAN SPECIALITY LP Pharmaceutical formulations useful in the treatment of insomnia Apr, 2027

(4 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: Method of treating insomnia characterized by difficulty with sleep onset

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;SUBLINGUAL Prescription
10MG TABLET;SUBLINGUAL Prescription

53. Drug name - ELEPSIA XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8163306 TRIPOINT Oral drug delivery system Sep, 2027

(4 years from now)

US8431156 TRIPOINT Pharmaceutical composition Oct, 2027

(5 years from now)

US8470367 TRIPOINT Oral drug delivery system Oct, 2027

(5 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM TABLET, EXTENDED RELEASE;ORAL Prescription
1.5GM TABLET, EXTENDED RELEASE;ORAL Prescription

54. Drug name - EMBEDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7682634 ALPHARMA PHARMS Pharmaceutical compositions Jun, 2027

(4 years from now)

US7682633 ALPHARMA PHARMS Pharmaceutical composition Jun, 2027

(4 years from now)

US8158156 ALPHARMA PHARMS Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist Jun, 2027

(4 years from now)

US8846104 ALPHARMA PHARMS Pharmaceutical compositions for the deterrence and/or prevention of abuse Jun, 2027

(4 years from now)

US8877247 ALPHARMA PHARMS Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist Jun, 2027

(4 years from now)

US7815934 ALPHARMA PHARMS Sequestering subunit and related compositions and methods Dec, 2027

(5 years from now)

Drugs and Companies using MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatement by orally administering an intact composition as claimed.

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG;0.8MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
30MG;1.2MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
50MG;2MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
60MG;2.4MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
80MG;3.2MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued
100MG;4MG CAPSULE, EXTENDED RELEASE;ORAL Discontinued

55. Drug name - EMEND

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MERCK Pharmaceutical composition of a tachykinin receptor antagonist Sep, 2027

(4 years from now)

Drugs and Companies using APREPITANT ingredient

Treatment: Prevention of postoperative nausea and vomiting; for the prevention of nausea and vomiting associated with chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Discontinued
80MG CAPSULE;ORAL Prescription
125MG CAPSULE;ORAL Prescription

56. Drug name - EMEND

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist Sep, 2027

(4 years from now)

Drugs and Companies using APREPITANT ingredient

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
125MG/KIT FOR SUSPENSION;ORAL Prescription

57. Drug name - EMPAVELI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169307 APELLIS PHARMS Potent compstatin analogs
Nov, 2027

(5 years from now)

US7888323 APELLIS PHARMS Potent compstatin analogs
Dec, 2027

(5 years from now)

US7989589 APELLIS PHARMS Compstatin analogs with improved activity
Dec, 2027

(5 years from now)

Drugs and Companies using PEGCETACOPLAN ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
1080MG/20ML (54MG/ML) SOLUTION;SUBCUTANEOUS Prescription

58. Drug name - ENTRESTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877938 NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9388134

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations May, 2027

(4 years from now)

US8877938

(Pediatric)

NOVARTIS PHARMS CORP Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations Nov, 2027

(5 years from now)

More Information on Dosage
Strength Dosage Availability
24MG;26MG TABLET;ORAL Prescription
49MG;51MG TABLET;ORAL Prescription
97MG;103MG TABLET;ORAL Prescription

59. Drug name - EPIDUO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8445543 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions Jul, 2027

(4 years from now)

US8071644 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions Jul, 2027

(4 years from now)

US8129362 GALDERMA LABS LP Combination/association of adapalene and benzoyl peroxide for treating acne lesions Jul, 2027

(4 years from now)

US8080537 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions Jul, 2027

(4 years from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.1%;2.5% GEL;TOPICAL Prescription

60. Drug name - ERLEADA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9388159 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators
Mar, 2027

(4 years from now)

CN101454002B JANSSEN BIOTECH For The Treatment Of Prostate Cancer And The Androgen Receptor-Related Disease Of Androgen Receptor Modulators
Mar, 2027

(4 years from now)

CN101454002A JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2656842A3 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2656841B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2004181A2 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2656842A2 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP3412290A1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2656841A1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP3100727B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP3412290B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2004181A4 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP3100727A1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2004181B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2656842B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2368550B1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2368550A1 JANSSEN BIOTECH Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9987261 JANSSEN BIOTECH Substituted diazaspiroalkanes as androgen receptor modulators Mar, 2027

(4 years from now)

US8802689 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases Mar, 2027

(4 years from now)

Drugs and Companies using APALUTAMIDE ingredient

Treatment: Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc); treatment of metastatic castration-sensitive prostate cancer (mcspc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription

61. Drug name - ESBRIET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7767700 GENENTECH INC Method of providing pirfenidone therapy to a patient Dec, 2027

(5 years from now)

US8420674 GENENTECH INC Method of providing pirfenidone therapy to a patient Dec, 2027

(5 years from now)

US7696236 GENENTECH INC Method of providing pirfenidone therapy to a patient Dec, 2027

(5 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Treatment: Pirfenidone dose escalation regimen for treatment of ipf as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Pirfenidone dose escalation regimen for treatment of fibrosis as 801 mg/day for days 1-7 of the regimen, 1602 mg/day for days 8-14 of the regimen, and 2403 mg/day for at least day 15 of the regimen; Dose escalation over 14 days for treatment of idiopathic pulmonary fibrosis

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
267MG CAPSULE;ORAL Prescription

62. Drug name - EUCRISA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501712 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents Feb, 2027

(4 years from now)

US9682092 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents Feb, 2027

(4 years from now)

US8501712

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents Aug, 2027

(4 years from now)

US9682092

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents Aug, 2027

(4 years from now)

Drugs and Companies using CRISABOROLE ingredient

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% OINTMENT;TOPICAL Prescription

63. Drug name - EVZIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system Feb, 2027

(4 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery Feb, 2027

(4 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery May, 2027

(4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/0.4ML (0.4MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

64. Drug name - EVZIO (AUTOINJECTOR)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system Feb, 2027

(4 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery Feb, 2027

(4 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery May, 2027

(4 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.4ML (2MG/0.4ML) SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS Discontinued

65. Drug name - FANAPT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8586610 VANDA PHARMS INC Methods for the administration of iloperidone Nov, 2027

(5 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are poor metabolizers of cyp2d6

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription
6MG TABLET;ORAL Prescription
8MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
12MG TABLET;ORAL Prescription

66. Drug name - FARXIGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

67. Drug name - FIBRICOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7741374 ATHENA Methods of use of fenofibric acid Aug, 2027

(4 years from now)

US7741373 ATHENA Methods of use of fenofibric acid Aug, 2027

(4 years from now)

US7915247 ATHENA Methods of use of fenofibric acid Aug, 2027

(4 years from now)

US7569612 ATHENA Methods of use of fenofibric acid Aug, 2027

(4 years from now)

Drugs and Companies using FENOFIBRIC ACID ingredient

Treatment: Adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet in patients with elevated cholesterol and/or lipid levels; Adjunctive therapy to diet to patients with hypertriglyceridemia; Adjunctive therapy to diet in patients with hyperlipidemias; adjunctive therapy to diet in patients with mixed dyslipidemia; adjunctive therapy to diet to patients with hypertriglyceridemia; Adjunctive therapy to diet in patients with hyperlipidemias

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
35MG TABLET;ORAL Discontinued
105MG TABLET;ORAL Prescription

68. Drug name - FINACEA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700076 LEO PHARMA AS Penetrating pharmaceutical foam Sep, 2027

(4 years from now)

US10117812 LEO PHARMA AS Foamable composition combining a polar solvent and a hydrophobic carrier Oct, 2027

(5 years from now)

US9265725 LEO PHARMA AS Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof Dec, 2027

(5 years from now)

Drugs and Companies using AZELAIC ACID ingredient

Treatment: Topical treatment of inflammatory papules and pustules of mild to moderate rosacea

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
15% AEROSOL, FOAM;TOPICAL Prescription

69. Drug name - FLOLIPID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10300041 TCG FLUENT PHARMA Liquid oral simvastatin compositions Apr, 2027

(4 years from now)

Drugs and Companies using SIMVASTATIN ingredient

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
20MG/5ML SUSPENSION;ORAL Prescription
40MG/5ML SUSPENSION;ORAL Prescription

70. Drug name - FORFIVO XL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7674479 ALMATICA Sustained-release bupropion and bupropion/mecamylamine tablets Jun, 2027

(4 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
450MG TABLET, EXTENDED RELEASE;ORAL Prescription

71. Drug name - GALAFOLD

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10383864 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

US9000011 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

US9480682 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

US10406143 AMICUS THERAP US Methods for treatment of fabry disease May, 2027

(4 years from now)

US9987263 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

US11241422 AMICUS THERAP US Methods for treatment of Fabry disease May, 2027

(4 years from now)

Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient

Treatment: The treatment of fabry patients

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 123MG BASE CAPSULE;ORAL Prescription

72. Drug name - GENOSYL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7560076 VERO BIOTECH Conversion of nitrogen dioxide (NO2) to nitric oxide (NO) Apr, 2027

(4 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage
Strength Dosage Availability
800PPM GAS;INHALATION Prescription

73. Drug name - GENVOYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7176220

(Pediatric)

GILEAD SCIENCES INC 4-oxoquinoline compound and use thereof as pharmaceutical agent Feb, 2027

(4 years from now)

US8981103

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound Apr, 2027

(4 years from now)

US7635704

(Pediatric)

GILEAD SCIENCES INC Stable crystal of 4-oxoquinoline compound Apr, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;150MG;200MG;EQ 10MG BASE TABLET;ORAL Prescription

74. Drug name - GILENYA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9187405 NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis Jun, 2027

(4 years from now)

US9187405

(Pediatric)

NOVARTIS S1P receptor modulators for treating relasping-remitting multiple sclerosis Dec, 2027

(5 years from now)

US10543179 NOVARTIS Dosage regimen of an S1P receptor modulator Dec, 2027

(5 years from now)

Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient

Treatment: Treatment of relapsing-remitting sclerosis (ms); Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.25MG BASE CAPSULE;ORAL Prescription
EQ 0.5MG BASE CAPSULE;ORAL Prescription

75. Drug name - GILOTRIF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539258

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases May, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 20MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 40MG BASE TABLET;ORAL Prescription

76. Drug name - GLYXAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors May, 2027

(4 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors May, 2027

(4 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations May, 2027

(4 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;5MG TABLET;ORAL Prescription
25MG;5MG TABLET;ORAL Prescription

77. Drug name - HALAVEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46965 EISAI INC Intermediates for the preparation of analogs of Halichondrin B Jan, 2027

(4 years from now)

Drugs and Companies using ERIBULIN MESYLATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1MG/2ML (0.5MG/ML) SOLUTION;INTRAVENOUS Prescription

78. Drug name - HYSINGLA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492389 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9775809 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9486412 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9084816 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9486413 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9095614 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9095615 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9545380 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492390 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
20MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE;ORAL Prescription
60MG TABLET, EXTENDED RELEASE;ORAL Prescription
80MG TABLET, EXTENDED RELEASE;ORAL Prescription
100MG TABLET, EXTENDED RELEASE;ORAL Prescription
120MG TABLET, EXTENDED RELEASE;ORAL Prescription

79. Drug name - IBRANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE47739 PFIZER 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
Mar, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription
100MG TABLET;ORAL Prescription
125MG TABLET;ORAL Prescription

80. Drug name - ICLUSIG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8114874 TAKEDA PHARMS USA Substituted acetylenic imidazo[1,2-B]pyridazine compounds as kinase inhibitors
Jan, 2027

(4 years from now)

EP2024366A4 TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
May, 2027

(4 years from now)

EP2024366B1 TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
May, 2027

(4 years from now)

EP2024366A2 TAKEDA PHARMS USA Monocyclic Heteroaryl Compounds
May, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 30MG BASE TABLET;ORAL Prescription
EQ 45MG BASE TABLET;ORAL Prescription

81. Drug name - ILUVIEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871241 ALIMERA SCIENCES INC Injectable sustained release delivery devices Aug, 2027

(4 years from now)

Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient

Treatment: NA

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage
Strength Dosage Availability
0.19MG IMPLANT;INTRAVITREAL Prescription

82. Drug name - IMBRUVICA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008309 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase
Nov, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8563563 PHARMACYCLICS INC Inhibitors of bruton's tyrosine kinase Apr, 2027

(4 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: Treatment of waldenstrom's macroglobulinemia; treatment of small lymphocytic lymphoma; treatment of chronic lymphocytic leukemia; treatment of chronic lymphocytic leukemia with 17p deletion; treatment of small lymphocytic lymphoma with 17p deletion

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
70MG CAPSULE;ORAL Prescription
140MG CAPSULE;ORAL Prescription

83. Drug name - IMCIVREE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9458195 RHYTHM Melanocortin receptor ligands
Oct, 2027

(5 years from now)

US8039435 RHYTHM Melanocortin receptor ligands
Oct, 2027

(5 years from now)

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG/ML BASE (EQ 10MG/ML BASE) SOLUTION;SUBCUTANEOUS Prescription

84. Drug name - IMPLANON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10821277 ORGANON Kit for and method of assembling an applicator for inserting an implant May, 2027

(4 years from now)

US8722037 ORGANON X-ray visible drug delivery device Sep, 2027

(4 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Treatment: NA

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage
Strength Dosage Availability
68MG/IMPLANT IMPLANT;IMPLANTATION Prescription

85. Drug name - INCRUSE ELLIPTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7488827 GLAXO GRP ENGLAND Muscarinic acetylcholine receptor antagonists
Dec, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXO GRP ENGLAND Medicament dispenser Oct, 2027

(4 years from now)

US8113199 GLAXO GRP ENGLAND Counter for use with a medicament dispenser Oct, 2027

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 62.5MCG BASE/INH POWDER;INHALATION Prescription

86. Drug name - INGREZZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto Nov, 2027

(5 years from now)

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription
EQ 60MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

87. Drug name - INJECTAFER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895612 AM REGENT Methods and compositions for administration of iron Jan, 2027

(4 years from now)

Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient

Treatment: Method of treatment of iron-related conditions with at least 0.6 grams of elemental iron via an iron carbohydrate complex, with a substantially non-immunogenic carbohydrate component, in about 15 minutes or less.; method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering at least about 0.6g of iron as ferric carboxymaltose in about 15 min or less; method of treating iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; method of treating iron deficiency anemia in adult patients who have non-dialysis dependent chronic kidney disease by intravenously administering about 1 g of iron as ferric carboxymaltose in about 15 minutes or less; method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by administering iv at least about 0.6 g of iron as ferric carboxymaltose in about 15 min or less; method of treating ida in adult patients with non-dialysis dependent chronic kidney disease & weighing at least 40 kg by intravenously administering at least about 0.6 grams of iron as ferric carboxymaltose in about 15 minutes or less

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
1GM IRON/20ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
750MG IRON/15ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
100MG IRON/2ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription
500MG IRON/10ML (50MG IRON/ML) SOLUTION;INTRAVENOUS Prescription

88. Drug name - INTERMEZZO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7658945 PURDUE PHARMA Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof Apr, 2027

(4 years from now)

Drugs and Companies using ZOLPIDEM TARTRATE ingredient

Treatment: Method for treating insomnia

Dosage: TABLET;SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
1.75MG TABLET;SUBLINGUAL Discontinued
3.5MG TABLET;SUBLINGUAL Discontinued

89. Drug name - INVOKAMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(5 years from now)

CN101573368A JANSSEN PHARMS A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.
Dec, 2027

(5 years from now)

CN101573368B JANSSEN PHARMS Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN200903871P4 JANSSEN PHARMS Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN286412B JANSSEN PHARMS Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B2 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224A1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

More Information on Dosage
Strength Dosage Availability
50MG;500MG TABLET;ORAL Prescription
50MG;1GM TABLET;ORAL Prescription
150MG;500MG TABLET;ORAL Prescription
150MG;1GM TABLET;ORAL Prescription

90. Drug name - INVOKAMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(5 years from now)

CN101573368A JANSSEN PHARMS A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.
Dec, 2027

(5 years from now)

CN101573368B JANSSEN PHARMS Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN200903871P4 JANSSEN PHARMS Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN286412B JANSSEN PHARMS Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B2 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224A1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

More Information on Dosage
Strength Dosage Availability
50MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
50MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
150MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription

91. Drug name - INVOKANA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7943788 JANSSEN PHARMS Glucopyranoside compound
Jul, 2027

(4 years from now)

US8513202 JANSSEN PHARMS Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate
Dec, 2027

(5 years from now)

CN101573368A JANSSEN PHARMS A Novel Crystalline Form Of 1-(Beta-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl]Benzene Hemihydrate With Favourable Characteristics Has Its X-Ray Powder Diffraction Pattern And/Or By Its Infrared Spectrum.
Dec, 2027

(5 years from now)

CN101573368B JANSSEN PHARMS Crystalline 1 - ([Beta] - D-Glucopyranosyl) - 4-Methyl-3 - [5 - (4-Fluorophenyl) - 2-Thienyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN200903871P4 JANSSEN PHARMS Crystalline Form Of 1-(B-D-Glucopyranosyl)-4-Methyl-3-[5-(4-Fluorophenyl)-2-Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

IN286412B JANSSEN PHARMS Crystalline Form Of 1-(B-Dglucopyranosyl)- 4-Methyl-3-[5-(4- Fluorophenyl)-2- Thienylmethyl] Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224B2 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

EP2102224A1 JANSSEN PHARMS Crystalline Form Of 1- (ß-D-Glucopyranosyl) -4 -Methyl- 3- [5- (4 -Fluorophenyl) -2-Thienylmethyl]Benzene Hemihydrate
Dec, 2027

(5 years from now)

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
300MG TABLET;ORAL Prescription

92. Drug name - JAKAFI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(5 years from now)

US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(5 years from now)

EP1966202B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Aug, 2027

(4 years from now)

EP1966202A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Aug, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Prescription
EQ 20MG BASE TABLET;ORAL Prescription
EQ 25MG BASE TABLET;ORAL Prescription

93. Drug name - JANUMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor May, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET;ORAL Prescription
500MG;EQ 50MG BASE TABLET;ORAL Prescription

94. Drug name - JANUMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor May, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

95. Drug name - JANUVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor May, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

96. Drug name - JARDIANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription
25MG TABLET;ORAL Prescription

97. Drug name - JENTADUETO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors May, 2027

(4 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET;ORAL Prescription
2.5MG;500MG TABLET;ORAL Prescription
2.5MG;850MG TABLET;ORAL Prescription

98. Drug name - JENTADUETO XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors May, 2027

(4 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors May, 2027

(4 years from now)

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription

99. Drug name - JULUCA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 50MG BASE;EQ 25MG BASE TABLET;ORAL Prescription

100. Drug name - JUXTAPID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7932268 AMRYT Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects Aug, 2027

(4 years from now)

Drugs and Companies using LOMITAPIDE MESYLATE ingredient

Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription
EQ 20MG BASE CAPSULE;ORAL Prescription
EQ 30MG BASE CAPSULE;ORAL Prescription
EQ 40MG BASE CAPSULE;ORAL Discontinued
EQ 60MG BASE CAPSULE;ORAL Discontinued

101. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; method of treating cystic fibrosis; treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/PACKET GRANULE;ORAL Prescription
50MG/PACKET GRANULE;ORAL Prescription
75MG/PACKET GRANULE;ORAL Prescription

102. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7495103 VERTEX PHARMS Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324242 VERTEX PHARMS Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Method of treating cystic fibrosis; method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET;ORAL Prescription

103. Drug name - KARBINAL ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9522191 AYTU Modified release formulations containing drug—ion exchange resin complexes Jun, 2027

(4 years from now)

Drugs and Companies using CARBINOXAMINE MALEATE ingredient

Treatment: NA

Dosage: SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
4MG/5ML SUSPENSION, EXTENDED RELEASE;ORAL Prescription

104. Drug name - KLISYRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001 ALMIRALL Compositions for modulating a kinase cascade and methods of use thereof Dec, 2027

(5 years from now)

Drugs and Companies using TIRBANIBULIN ingredient

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% OINTMENT;TOPICAL Prescription

105. Drug name - KORSUVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10793596 CARA THERAP Synthetic peptide amides
Nov, 2027

(5 years from now)

US8536131 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(5 years from now)

US10017536 CARA THERAP Synthetic peptide amides and dimers thereof
Nov, 2027

(5 years from now)

US7402564 CARA THERAP Synthetic peptide amides
Nov, 2027

(5 years from now)

US7713937 CARA THERAP Synthetic peptide amides and dimeric forms thereof
Nov, 2027

(5 years from now)

US7727963 CARA THERAP Synthetic peptide amides
Nov, 2027

(5 years from now)

CN101627049A CARA THERAP Synthetic Phthalamide
Nov, 2027

(5 years from now)

CN101627049B CARA THERAP Synthetic Phthalamide
Nov, 2027

(5 years from now)

CN101535336B CARA THERAP Synthesizing Phthalic Amide And The Dimer
Nov, 2027

(5 years from now)

CN101535336A CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

IN200903250P4 CARA THERAP Synthetic Peptide Amides
Nov, 2027

(5 years from now)

IN298634B CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

IN298624B CARA THERAP Synthetic Peptide Amides
Nov, 2027

(5 years from now)

IN200903251P4 CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

EP2064228A2 CARA THERAP Synthetic Peptide Amides
Nov, 2027

(5 years from now)

EP2064228B1 CARA THERAP Synthetic Peptide Amides
Nov, 2027

(5 years from now)

EP2079756A2 CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

EP2079756B1 CARA THERAP Synthetic Peptide Amides And Dimers Thereof
Nov, 2027

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217007 CARA THERAP Synthetic peptide amides Nov, 2027

(5 years from now)

US8236766 CARA THERAP Uses of synthetic peptide amides Nov, 2027

(5 years from now)

US8486894 CARA THERAP Synthetic peptide amides and dimeric forms thereof Nov, 2027

(5 years from now)

US9334305 CARA THERAP Synthetic peptide amides and dimers thereof Nov, 2027

(5 years from now)

US9359399 CARA THERAP Synthetic peptide amides Nov, 2027

(5 years from now)

US10138270 CARA THERAP Synthetic peptide amides Nov, 2027

(5 years from now)

Drugs and Companies using DIFELIKEFALIN ACETATE ingredient

Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

106. Drug name - KYBELLA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7622130 KYTHERA BIOPHARMS Methods and compositions for the non-surgical removal of fat Dec, 2027

(5 years from now)

US7754230 KYTHERA BIOPHARMS Methods and related compositions for reduction of fat Dec, 2027

(5 years from now)

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Treatment: Method for reduction of submental fat

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
20MG/2ML (10MG/ML) SOLUTION;SUBCUTANEOUS Prescription

107. Drug name - KYNAMRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7511131 KASTLE THERAPS LLC Antisense modulation of apolipoprotein B expression
Jan, 2027

(4 years from now)

Drugs and Companies using MIPOMERSEN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
200MG/ML (200MG/ML) SOLUTION;SUBCUTANEOUS Discontinued

108. Drug name - KYPROLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7737112 ONYX THERAP Composition for enzyme inhibition Dec, 2027

(5 years from now)

Drugs and Companies using CARFILZOMIB ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
10MG/VIAL POWDER;INTRAVENOUS Prescription
30MG/VIAL POWDER;INTRAVENOUS Prescription
60MG/VIAL POWDER;INTRAVENOUS Prescription

109. Drug name - LASTACAFT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10617695 ALLERGAN Ophthalmic compositions containing alcaftadine Mar, 2027

(4 years from now)

US8664215 ALLERGAN Ocular allergy treatments with alcaftadine Dec, 2027

(5 years from now)

Drugs and Companies using ALCAFTADINE ingredient

Treatment: Use of lastacaft to temporary relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.25% SOLUTION/DROPS;OPHTHALMIC Over the counter

110. Drug name - LENVIMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006256 EISAI INC Antitumor agent for thyroid cancer Jul, 2027

(4 years from now)

Drugs and Companies using LENVATINIB MESYLATE ingredient

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 4MG BASE CAPSULE;ORAL Prescription
EQ 10MG BASE CAPSULE;ORAL Prescription

111. Drug name - LEQVIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8809292 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene
May, 2027

(4 years from now)

IN200806166P4 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

IN269138B NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584047B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3249052A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3249052B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2835429A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3578656A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584048A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584047A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2194128A1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP3578656B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2584048B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2835429B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

EP2194128B1 NOVARTIS Compositions And Methods For Inhibiting Expression Of The Pcsk9 Gene
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8222222 NOVARTIS Compositions and methods for inhibiting expression of the PCSK9 gene Dec, 2027

(5 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) SOLUTION;SUBCUTANEOUS Prescription

112. Drug name - LETAIRIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474752 GILEAD Method for treating a pulmonary hypertension condition Dec, 2027

(5 years from now)

US8377933 GILEAD Method for treating a pulmonary hypertension condition Dec, 2027

(5 years from now)

Drugs and Companies using AMBRISENTAN ingredient

Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

113. Drug name - LEVITRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8273876 BAYER HLTHCARE Medicaments containing vardenafil hydrochloride trihydrate Jul, 2027

(4 years from now)

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Treatment: Treatement of erectiile dysfunction by administering a film-coated tablet

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE TABLET;ORAL Discontinued
EQ 5MG BASE TABLET;ORAL Discontinued
EQ 10MG BASE TABLET;ORAL Discontinued
EQ 20MG BASE TABLET;ORAL Discontinued

114. Drug name - LEXISCAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(4 years from now)

EP1989214A1 ASTELLAS Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Feb, 2027

(4 years from now)

EP1989214B1 ASTELLAS Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Feb, 2027

(4 years from now)

EP1989214B8 ASTELLAS Process For Preparing An A2A-Adenosine Receptor Agonist And Its Polymorphs
Feb, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs Feb, 2027

(4 years from now)

Drugs and Companies using REGADENOSON ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
0.4MG/5ML (0.08MG/ML) SOLUTION;INTRAVENOUS Prescription

115. Drug name - LUMIGAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7851504 ALLERGAN Enhanced bimatoprost ophthalmic solution
Jun, 2027

(4 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.01% SOLUTION/DROPS;OPHTHALMIC Prescription

116. Drug name - LYNPARZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143241 ASTRAZENECA DNA damage repair inhibitors for treatment of cancer Aug, 2027

(4 years from now)

US8071579 ASTRAZENECA DNA damage repair inhibitors for the treatment of cancer Aug, 2027

(4 years from now)

Drugs and Companies using OLAPARIB ingredient

Treatment: Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; Maintenance treatment of deleterious or suspected deleterious gbrca-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen; treatment of hr-positive, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, and with endocrine therapy or are inappropriate for endocrine therapy; maintenance treatment of recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; treatment of deleterious or suspected deleterious germline brca-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy; treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; maintenance treatment of brca-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability; treatment of deleterious or suspected deleterious germline or somatic brca-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; maintenance treatment with bevacizumab of primary peritoneal cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, which has progressed following prior treatment with enzalutamide or abiraterone; maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of adv. epithelial ovarian cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with a deleterious or suspected deleterious brca mutation; maintenance treatment with bevacizumab of fallopian tube cancer in complete or partial response to first-line platinum chemotherapy and homologous recombination deficiency-positive with genomic instability

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
50MG CAPSULE;ORAL Discontinued

117. Drug name - LYRICA CR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945620

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin May, 2027

(4 years from now)

US9144559

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin May, 2027

(4 years from now)

US10022447

(Pediatric)

UPJOHN Solid pharmaceutical compositions containing pregabalin May, 2027

(4 years from now)

Drugs and Companies using PREGABALIN ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
82.5MG TABLET, EXTENDED RELEASE;ORAL Prescription
165MG TABLET, EXTENDED RELEASE;ORAL Prescription
330MG TABLET, EXTENDED RELEASE;ORAL Prescription

118. Drug name - MACRILEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8192719 NOVO Methods and kits to diagnose growth hormone deficiency by oral administration of EP 1572 or EP 1573 compounds Oct, 2027

(5 years from now)

Drugs and Companies using MACIMORELIN ACETATE ingredient

Treatment: A method for the diagnosis of adult growth hormone deficiency by measuring the level of growth hormone after oral administration of macimorelin

Dosage: FOR SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 60MG BASE/POUCH FOR SOLUTION;ORAL Prescription

119. Drug name - MEKINIST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7378423 NOVARTIS Pyrimidine compound and medical use thereof
May, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 0.5MG TABLET;ORAL Prescription
EQ 1MG TABLET;ORAL Discontinued
EQ 2MG TABLET;ORAL Prescription

120. Drug name - MOXATAG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8299052 PRAGMA Pharmaceutical compositions and methods for improved bacterial eradication May, 2027

(4 years from now)

Drugs and Companies using AMOXICILLIN ingredient

Treatment: Use of once-a-day amoxicillin product to treat tonsillitis and/or pharyngitis secondary to streptococcus pyogenes

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
775MG TABLET, EXTENDED RELEASE;ORAL Discontinued

121. Drug name - NEUPRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8246979 UCB INC Transdermal delivery system for the administration of rotigotine Sep, 2027

(4 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Treatment: Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system; treatment of restless legs syndrome by application of claimed transdermal delivery system

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
1MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
2MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
3MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
4MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
6MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription
8MG/24HR FILM, EXTENDED RELEASE;TRANSDERMAL Prescription

122. Drug name - NEVANAC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7834059 NOVARTIS Topical nepafenac formulations Jan, 2027

(4 years from now)

Drugs and Companies using NEPAFENAC ingredient

Treatment: Method of treating ocular inflammation

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% SUSPENSION/DROPS;OPHTHALMIC Prescription

123. Drug name - NEXAVAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8877933 BAYER HLTHCARE Thermodynamically stable form of a tosylate salt
Dec, 2027

(5 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 200MG BASE TABLET;ORAL Prescription

124. Drug name - NEXICLON XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8337890 ATHENA Modified release formulations containing drug-ion exchange resin complexes Apr, 2027

(4 years from now)

Drugs and Companies using CLONIDINE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 0.17MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 0.26MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

125. Drug name - NINLARO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8003819 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US8530694 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

US7687662 TAKEDA PHARMS USA Proteasome inhibitors
Aug, 2027

(4 years from now)

CN101772507B TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

CN102961387B TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

CN105837608A TAKEDA PHARMS USA Proteasome Inhibitor And Composition And Application Thereof
Aug, 2027

(4 years from now)

CN105837608B TAKEDA PHARMS USA Proteasome Inhibitors And Compositions And Uses Thereof
Aug, 2027

(4 years from now)

CN102961387A TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

CN101772507A TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

EP2178888A1 TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

EP2178888B1 TAKEDA PHARMS USA Proteasome Inhibitors
Aug, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871745 TAKEDA PHARMS USA Proteasome inhibitors Aug, 2027

(4 years from now)

Drugs and Companies using IXAZOMIB CITRATE ingredient

Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 2.3MG BASE CAPSULE;ORAL Prescription
EQ 3MG BASE CAPSULE;ORAL Prescription
EQ 4MG BASE CAPSULE;ORAL Prescription

126. Drug name - NOURIANZ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318201 KYOWA KIRIN Method of stabilizing diarylvinylene compound Sep, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
20MG TABLET;ORAL Prescription
40MG TABLET;ORAL Prescription

127. Drug name - OCALIVA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE48286 INTERCEPT PHARMS INC Steroids as agonists for FXR
Feb, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

128. Drug name - OLEPTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7829120 ANGELINI PHARMA Trazodone composition for once a day administration Mar, 2027

(4 years from now)

Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient

Treatment: Method of treating depression

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET, EXTENDED RELEASE;ORAL Discontinued
300MG TABLET, EXTENDED RELEASE;ORAL Discontinued

129. Drug name - ONGENTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8907099 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9745290 NEUROCRINE Dosage regimen for COMT inhibitors Oct, 2027

(5 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
50MG CAPSULE;ORAL Prescription

130. Drug name - ONIVYDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8329213 IPSEN INC Liposomes useful for drug delivery
Jan, 2027

(4 years from now)

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) INJECTABLE, LIPOSOMAL;INTRAVENOUS Prescription

131. Drug name - ONPATTRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642076 ALNYLAM PHARMS INC Lipid containing formulations Oct, 2027

(5 years from now)

Drugs and Companies using PATISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 10MG BASE/5ML (EQ 2MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

132. Drug name - ONSOLIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597288 BDSI Transmucosal delivery devices with enhanced uptake Jul, 2027

(4 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: Management of breakthrough pain in patients with cancer

Dosage: FILM;BUCCAL

More Information on Dosage
Strength Dosage Availability
EQ 0.2MG BASE FILM;BUCCAL Discontinued
EQ 0.4MG BASE FILM;BUCCAL Discontinued
EQ 0.6MG BASE FILM;BUCCAL Discontinued
EQ 0.8MG BASE FILM;BUCCAL Discontinued
EQ 1.2MG BASE FILM;BUCCAL Discontinued

133. Drug name - ONZETRA XSAIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10124132 CURRAX Nasal delivery Mar, 2027

(4 years from now)

US10398859 CURRAX Nasal delivery devices Dec, 2027

(5 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; acute treatment of migraine

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
EQ 11MG BASE POWDER;NASAL Prescription

134. Drug name - OPANA ER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8808737 ENDO PHARMS Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment Jun, 2027

(4 years from now)

Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient

Treatment: Method of administration of controlled release oxymorphone

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
7.5MG TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG TABLET, EXTENDED RELEASE;ORAL Discontinued
15MG TABLET, EXTENDED RELEASE;ORAL Discontinued
20MG TABLET, EXTENDED RELEASE;ORAL Discontinued
30MG TABLET, EXTENDED RELEASE;ORAL Discontinued
40MG TABLET, EXTENDED RELEASE;ORAL Discontinued

135. Drug name - OPSUMIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265762 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide May, 2027

(4 years from now)

Drugs and Companies using MACITENTAN ingredient

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 3% of the weight of said pharmaceutical composition

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET;ORAL Prescription

136. Drug name - OPZELURA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7598257 INCYTE CORP Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Dec, 2027

(5 years from now)

US8415362 INCYTE CORP Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Dec, 2027

(5 years from now)

EP1966202B1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Aug, 2027

(4 years from now)

EP1966202A1 INCYTE CORP Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
Aug, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1.5% BASE CREAM;TOPICAL Prescription

137. Drug name - ORACEA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7749532 GALDERMA LABS LP Once daily formulations of tetracyclines Dec, 2027

(5 years from now)

Drugs and Companies using DOXYCYCLINE ingredient

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Prescription

138. Drug name - ORKAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and ivacaftor

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
125MG/PACKET;100MG/PACKET GRANULE;ORAL Prescription
188MG/PACKET;150MG/PACKET GRANULE;ORAL Prescription

139. Drug name - OVIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7560445 TARO PHARM INDS LTD Process for preparing malathion for pharmaceutical use
Feb, 2027

(4 years from now)

Drugs and Companies using MALATHION ingredient

Treatment: NA

Dosage: LOTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.5% LOTION;TOPICAL Discontinued

140. Drug name - OXTELLAR XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9351975 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US8821930 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US11166960 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US9855278 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US7910131 SUPERNUS PHARMS Method of treating seizures using modified release formulations of oxcarbazepine Apr, 2027

(4 years from now)

US9119791 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US9370525 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US10220042 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US8617600 SUPERNUS PHARMS Modified release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

US7722898 SUPERNUS PHARMS Modified-release preparations containing oxcarbazepine and derivatives thereof Apr, 2027

(4 years from now)

Drugs and Companies using OXCARBAZEPINE ingredient

Treatment: Treatment of partial-onset seizures

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
150MG TABLET, EXTENDED RELEASE;ORAL Prescription
300MG TABLET, EXTENDED RELEASE;ORAL Prescription
600MG TABLET, EXTENDED RELEASE;ORAL Prescription

141. Drug name - OXYCONTIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8894988 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9763933 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9770416 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US8808741 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492393 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492391 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492389 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9492392 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

US9775808 PURDUE PHARMA LP Tamper resistant dosage forms Aug, 2027

(4 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG TABLET, EXTENDED RELEASE;ORAL Prescription
15MG TABLET, EXTENDED RELEASE;ORAL Prescription
20MG TABLET, EXTENDED RELEASE;ORAL Prescription
30MG TABLET, EXTENDED RELEASE;ORAL Prescription
40MG TABLET, EXTENDED RELEASE;ORAL Prescription
60MG TABLET, EXTENDED RELEASE;ORAL Prescription
80MG TABLET, EXTENDED RELEASE;ORAL Prescription

142. Drug name - OZEMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687611 NOVO Injection device with torsion spring and rotatable display Feb, 2027

(4 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism Sep, 2027

(4 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/1.5ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription
4MG/3ML (1.34MG/ML) SOLUTION;SUBCUTANEOUS Prescription

143. Drug name - PENNSAID

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8871809 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9168304 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9339551 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9066913 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9168305 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9132110 HORIZON Treatment of pain with topical diclofenac Oct, 2027

(5 years from now)

US9220784 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9339552 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9539335 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US8563613 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

US9101591 HORIZON Diclofenac topical formulation Oct, 2027

(5 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Treatment: Use of topical diclofenac sodium for treating pain; Use of topical diclofenac for treating pain

Dosage: SOLUTION;TOPICAL

More Information on Dosage
Strength Dosage Availability
2% SOLUTION;TOPICAL Prescription

144. Drug name - PHOSLYRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089528 FRESENIUS MEDCL Liquid compositions of calcium acetate Jul, 2027

(4 years from now)

US8592480 FRESENIUS MEDCL Liquid compositions of calcium acetate Jul, 2027

(4 years from now)

Drugs and Companies using CALCIUM ACETATE ingredient

Treatment: Use of phoslyra for reduction of serum phosphorous in patients

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
667MG/5ML SOLUTION;ORAL Prescription

145. Drug name - PICATO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8278292 LEO LABS Therapeutic compositions Jul, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
0.015% GEL;TOPICAL Discontinued
0.05% GEL;TOPICAL Discontinued

146. Drug name - PRADAXA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7866474 BOEHRINGER INGELHEIM Film container Aug, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE CAPSULE;ORAL Prescription
EQ 110MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

147. Drug name - PREZCOBIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700645

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor Jun, 2027

(4 years from now)

More Information on Dosage
Strength Dosage Availability
150MG;800MG TABLET;ORAL Prescription

148. Drug name - PREZISTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7700645

(Pediatric)

JANSSEN PRODS Pseudopolymorphic forms of a HIV protease inhibitor Jun, 2027

(4 years from now)

Drugs and Companies using DARUNAVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG TABLET;ORAL Prescription
150MG TABLET;ORAL Prescription
300MG TABLET;ORAL Discontinued
400MG TABLET;ORAL Discontinued
600MG TABLET;ORAL Prescription
800MG TABLET;ORAL Prescription

149. Drug name - PRISTIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8269040 PF PRISM CV Derivatives of venlafaxine and methods of preparing and using the same
Jul, 2027

(4 years from now)

Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

150. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9925157 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(4 years from now)

US9925158 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(4 years from now)

US9925156 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof
Jan, 2027

(4 years from now)

EP2535044B1 HORIZON Enterically Coated Cysteamine Bitartrate And Cystamine
Jan, 2027

(4 years from now)

EP2535044A1 HORIZON Enterically Coated Cysteamine Bitartrate And Cystamine
Jan, 2027

(4 years from now)

EP1919458A4 HORIZON Enterically Coated Cysteamine, Cystamine And Derivatives Thereof
Jan, 2027

(4 years from now)

EP1919458B3 HORIZON Enterically Coated Cysteamine, Cystamine And Derivatives Thereof
Jan, 2027

(4 years from now)

EP1919458B1 HORIZON Enterically Coated Cysteamine, Cystamine And Derivatives Thereof
Jan, 2027

(4 years from now)

EP1919458A2 HORIZON Enterically Coated Cysteamine, Cystamine And Derivatives Thereof
Jan, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9192590 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9198882 HORIZON Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9192590

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof Jul, 2027

(4 years from now)

US9198882

(Pediatric)

HORIZON Enterically coated cysteamine, cystamine and derivatives thereof Jul, 2027

(4 years from now)

US8026284 HORIZON Enterically coated cystamine, cysteamine and derivatives thereof Sep, 2027

(4 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription
EQ 75MG BASE CAPSULE, DELAYED RELEASE;ORAL Prescription

151. Drug name - PROCYSBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9925157 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9925158 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9192590 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9198882 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9925156 HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jan, 2027

(4 years from now)

US9198882

(Pediatric)

HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jul, 2027

(4 years from now)

US9192590

(Pediatric)

HORIZON PHARMA USA Enterically coated cysteamine, cystamine and derivatives thereof Jul, 2027

(4 years from now)

US8026284 HORIZON PHARMA USA Enterically coated cystamine, cysteamine and derivatives thereof Sep, 2027

(4 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses

Dosage: GRANULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription
EQ 300MG BASE/PACKET GRANULE, DELAYED RELEASE;ORAL Prescription

152. Drug name - PROMACTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8062665 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug, 2027

(4 years from now)

US8071129 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) Aug, 2027

(4 years from now)

US8052994 NOVARTIS 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)